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Aim: To find putative diagnostic markers for clear cell renal cell carcinomas (ccRCC). Material and methods: Quantitative polymerase 
chain reaction (Q-PCR), bisulfite treatment, methylation-specific PCR, analysis on cBioPortal for Cancer Genomics. Results: We have 
found that expression of GPX 1, GPX3, and GPX4 genes was decreased in ccRCC. We have shown that the number of alanine (GCG) 
repeats at the amino terminus of the GPX1 protein is variable. It was reported earlier that an allele that possess 5 alanine repeats is as-
sociated with the increased cancer risk. According to the obtained data, the allele with the 5 alanine repeats was also present in a group 
of healthy donors. Moreover, the frequency of alleles with repeats was similar among ccRCC patients and healthy individuals. We found 
that decreased expression of GPXs genes was not associated with promoter methylation. To provide other explanation, an analysis on the 
gene copy number was performed. We have found the heterozygous deletions for GPX1 gene, amplification for GPX3 gene, and no change 
in gene copy number for GPX4. Conclusions: Our data support the hypothesis that GPX1, GPX3, and GPX4 genes may play a role in ccRCC 
cancerogenesis and therefore they might be considered as putative diagnostic markers for ccRCC.
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The clear cell renal cell carcinoma (ccRCC) repre-
sents an invasive and the most common adult kidney 
neoplasm. ccRCC is one of the most therapy-resistant 
carcinomas, responding very poorly to radio-, chemo-, 
and hormonal therapy [1]. So, there is an urgent need 
to study and understand the molecular mechanisms 
of ccRCC cancerogenesis with the aim to reveal the early 
diagnostic markers.
It is well known that cancer cells produce high 
amounts of reactive oxygen species that play an impor-
tant role in induction of apoptosis. Cancer cells evade 
apoptosis, as a rule. One of mechanisms to evade apop-
tosis is removal of hydroperoxide. This process is under 
control by antioxidant enzymes that are represented 
by a family of glutathione peroxidases (GPXs) [2, 3].
Human GPXs family consists of 8 members; the five 
of them contain selenocysteine in an active center 
(GPX1/GPX2/GPX3/GPX4/GPX6) and other three are 
cysteine-containing proteins (GPX5/GPX7/GPX8). 
Proteins that contain selenocysteine, or selenium 
in the form of amino acid, are designated as selenopro-
teins. GPX proteins are implicated in cancerogenesis; 
however, the role of selenoproteins of GPX family is not 
fully understood. Moreover, each protein of GPX family 
might show different functions.
For example, gene GPX1 is localized on chromo-
some 3p21. This locus frequently associated with 
the loss of heterozygosity in cancers. The loss of hete-
rozygosity for GPX1 was found in lung, breast, head 
and neck, and colon cancers [4]. Another genetic 
alteration is polymorphism that involves a variable 
number of “GCG” tri-nucleotide repeats in the first 
exon of the GPX1 gene. This results in five, six, or seven 
alanines near the N-terminus. The higher number 
of repeats is associated with cancer of several types; 
it is not clear, however, which allele influences on can-
cer development [5].
An expression level of the GPX2 is increased 
in breast [6] and colorectal cancers [7, 8].
It is shown also that after transfection with 
a GPX3 expression construct into different prostate 
cancer cell lines (PC-3, DU145, and LNCaP) trans-
fected cells exhibited decreased ability to proliferate 
in soft agar [9].
Expression of the GPX4 is decreased in pancre-
atic cancer cell lines, compared with normal human 
pancreas [10]. There is no data on expression pattern 
of the GPX6 in cancer.
The present work is devoted to a study on the role 
of genes encoding selenium-containing GPXs 
in ccRCC cancerogenesis.
MATERIALS AND METHODS
Tissue samples. All samples of tissue were ob-
tained in accordance with the permission from the Ethi-
cal Committee of the Institute of Molecular Biology and 
Genetics of the NAS of Ukraine.
Surgically removed tumors and surrounding rim 
of normal tissues were obtained from Kyiv National 
Urological Center (Ukraine). All tumor samples were 
characterized, according to the International System 
of Clinico-Morphological Classification of Tumors 
(TNM), based on the tumor-node-metastasis and 
staging classification (1989) [11] and WHO criteria 
classification (1999) [12]. The mean age of patients 
was 56 ± 3.75 years, with a male to female ratio 
of 58 : 42, respectively. The samples were grouped, 
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according to the stage of tumor development and ar-
ranged in order of increasing atypia.
DNA of healthy donors was received from Insti-
tute of Gerontology of the NAMS of Ukraine (License 
of the Ministry of Health AB 511829). The mean age 
of patients was 65 ± 4.5 years, with a male to female 
ratio of 1 : 1.
Isolation of genomic DNA and total RNA. Ge-
nomic DNA was isolated, using the DNA purification 
Kit (Fermentas, Lithuania), according to the manufac-
turer’s recommendations. Total RNA was extracted 
with the RNeasy Mini Kit (QIAGEN, USA), following 
the producer’s protocol. Quality of genomic DNA 
and total RNA was assessed by agarose gel electro-
phoresis; their concentration was measured, using 
a spectrophotometer Nano Drop ND-1000 (Nano-
Drop Technologies Inc., USA). The samples, used for 
the quantitative polymerase chain reaction (Q-PCR), 
were of high molecular weight and pure from con-
taminations (an OD 260/280 ranging from 1.6 to 1.8). 
From each RNA sample, 1 μg of total RNA was treated 
with DNAse I and reversely transcribed in duplicates, 
as well as negative controls without enzyme, using 
the RevertAid™ H Minus First Strand cDNA Synthesis 
Kit (Thermo Scientific, SE, Sweden).
Analysis of gene expression levels. The analy-
sis of relative expression of genes was performed 
for GPX1 and GPX3 on 12 ccRCC samples and 
corresponding normal tissues, and for 16 paired 
samples for GPX-2, -4, and -6 by Q-PCR, using 
the IQ5 Cycler (Bio Rad, USA) and Mastermix SYBR 
Green (Thermo Scientific, SE, Sweden) according 
to the manufacturer’s instruction. Primers for each 
gene (Table 1) were designed, using the Primer3 pro-
gram (http://frodo.wi.mit.edu/primer3/). Each Q-PCR 
reaction mix contained 12.5 μl of 2 × SYBR Green PCR 
Master Mix (Fermentas, USA), 0.3 mM of primers, 
10 ng/μl cDNA, and a nuclease-free water to make 
a total volume of 25 μl. TBP was used as reference 
gene [13]. The change of expression was calculated 
with ΔΔCt method of relative quantification [14].
Table 1. Primers for target and reference genes to study expression levels
Gene Forward primer Reverse primer
GPX1
GPX2
GPX3
CCAAGCTCATCACCTGGTCT
TTTTGGACAAGGGTGAAGGT
TACGAGTACGGAGCCCTCAC
TCGATGTCAATGGTCTGGAA 
TGCAACCAATTTGGACATCA
CCAGAATGACCAGACCGAAT
GPX4 ATGTCCTTGGCGGAAAACTC CCTTGGGTTGGATCTTCATC
GPX6 AGGGTGAGGGCTCCATACTC AGTTCCAGGCCTCCTGTCTT
TBP GAACCACGGCACTGATTTTC CACAGCTCCCCACCATATTC
PCR conditions: 50 °C × 2 min, 95 °C × 10 min, 35 cycles of 95 °C × 20 s, 
60 °C × 20 s 72 °C × 40 s.
Analysis of trinucleotide repeat variations. Ana-
lysis of trinucleotide repeat variations was performed 
on 40 ccRCC and 41 normal tissues. The reaction con-
ditions and sequence of primers are shown in Table 2. 
Forward primer was labelled by Cy5dye (IBA, USA).
Table 2. Primers for GPX1 to study the GCG repeat polymorphism (num-
ber of Ala repeats)
Gene Forward primer Reverse primer
GPX1 Су5-GAAAACTGCCTCTGC-
CACGTGACC
TGCAACCAATTTGGACATCA
PCR conditions: 94 °C × 2 min, 28 cycles of 94 °C × 30 s, 68 °C × 20 s 72 °C × 60 s.
Denaturing PAAG electrophoresis was used 
to determine the exact size of trinucleotide repeats. 
The electrophoresis was conducted on automatic 
laser sequencing machine “ALF express” (Pharmacia 
Biotech, USA). The mixture that contained 3 μl of ampli-
fication product and 2 μl of loading buffer (0.01% brom-
phenol blue, 0.01% xylene cyanol, 98% formamide), 
was denatured at 95 °C for 5 min before electrophoresis.
Identification of CpG islands in the promoter 
region of GPX genes. The CpG islands in the pro-
moter region of GPXs were defined, using CpG island 
searcher online tool (http://www.uscnorris.com/ 
cpgislands2/cpg.aspx).
DNA bisulfite treatment and methylation-
specific PCR (MSP). Bisulfite modification of the pu-
rified DNA from 25 ccRCC samples along with 
25 corresponding normal tissues was achieved, using 
the EZ DNA Methylation Kit (Zymo Research Corpora-
tion, USA), following the producer’s protocol. Methyl 
specific Q-PCR was done. Each Q-PCR reaction mix 
contained 12.5 μl of 2 × SYBR Green PCR Master Mix 
(Thermo Scientific, SE, Sweden), 0.3 mM of primer, 
10 ng/μl of genomic DNA, and a nuclease-free water 
to make a total volume of 25 μl. Q-PCR was car-
ried out for 35 cycles comprising 15 s denaturation 
at 95 °C and 60 s annealing at 60 °C. The cycling was 
started by 50 °C × 2 min, 95 °C × 10 min. Primers for 
MSP (Table 3) targeting CpG-rich promoter region 
were designed, using online software “MethPrimer” 
(http://www.urogene.org/methprimer/). COL2A1- was 
used as reference gene.
Table 3. Primers for target and reference genes to study deletion search 
and methylation analysis
Gene Forward primer Reverse primer
GPX1M
GPX1unM
CTAACCGAACAACACACATAACG
ACCAAACAACACACATAACACA
GAGGCGGGATTTTTAGGTTC
ATGAGGTGGGATTTTTAGGTTT
GPX3M
GPX3unM
GTTGAGGGTAAGTCGCGTTC
GAGTTGAGGGTAAGTTGTGTTTGT
GTCCGTCTAAAATATCCGACG
CCATCCATCTAAAATATCCAA-
CACT
GPX4M
GPX4unM
GTTGGAAATTTCGGATTACGC
GGGTTGGAAATTTTGGATTATGT
ACCGTAATCAAAACTACGCG
CCAAAAACCATAATCAAAAC-
TACAA
COL2A1 GTAATGTTAGGAGTATTTTGTGGGA CTACCCCAAAAAAACCCAATCCTA
Analysis of gene copy number variation. Analy-
sis of variation of gene copy number was performed 
on 12 ccRCC samples, in parallel with normal tissues 
from the same patients, as described earlier [14].
Analysis of the open-access bio-database. 
The cBioPortal for Cancer Genomics provides 
visuali zation, analysis and download of large-scale 
cancer genomics data sets (http://cbioportal.org). 
Analysis of 415 ccRCC samples in comparison with 
 corresponding normal tissues was performed in silico.
Statistical analysis. Allele frequency and geno-
type analysis was performed, using the Hardy — 
Weinberg equilibrium with Genepop v4 software 
(http://genepop.curtin.edu.au/) [15]. The Nonpara-
metric Wilcoxon test was used to compare mRNA 
expression of target and reference genes for the same 
sample. Groups of samples were compared in re-
spect to average level of mRNA decrease (LDav) and 
the frequency of decrease (FD). The LD was calcu-
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lated as 1/R and reflects the n-fold factor by which 
the mRNA content decreased in the tumor compared 
to normal tissue. Nonparametric Kruskal — Wallis and 
Mann — Whitney rank-sum tests were used to test 
mRNA differences (both LDav and FD) for each target 
gene. The Nonparametric Spearmen’s criterion was 
used to calculate the coefficient of correlation between 
the LDav for each set of pairs of target genes. P-values 
< 0.05 were considered statistically significant. All sta-
tistical proce dures were performed using the BioStat 
software.
RESULTS AND DISCUSSION
E xpression of  the GPX family  genes 
in ccRCC. We have studied expression of all five 
selenium-containing GPXs.
GPX1. We have shown that GPX1 expression was 
decreased in 85% (9 of 12) of ccRCC cases.
Protein, encoded by GPX1 that is located on chro-
mosome 3p21.3, was found in the cytosol and mito-
chondria. The primary function of GPX1 protein is de-
toxifying of hydroperoxides. GPX1 cannot be replaced 
by any other selenoprotein in protecting from genera-
lized oxidative stress. GPX1 can prevent DNA mutations 
due to oxidative stressand also counteracts production 
of COX/LOX-derived pro-inflammatory mediators. 
Thereby, GPX1 might prevent cancerogenesis, at least 
at the initiation stage [16]. Few studies have shown pro-
tective effect of GPX1; GPX1 overexpression resulted 
in reduced proliferation of tumor cell lines in vitro and 
in experimental animals (xenograft model) [17].
GPX1 is polymorphic at several positions and some 
alleles have been associated with the increased cancer 
risk. The most studied GPX1 polymorphism is proline/
leucine variation at codon 198. Another example of poly-
morphism is the variable number of alanine (GCG) re-
peats at the amino terminus of the protein. It was shown 
that there are three different types of alleles, with five, six 
or seven (Ala) repeats in this sequence. It was also re-
ported that there is an association of allele with 5 alanine 
repeats and the increased the risk of prostate cancer 
in young patients [18]. So, we wanted to investigate 
the relationship between the GCG repeat polymorphism 
in GPX1 sequence and ccRCC cancerogenesis.
An analysis of the GCG repeat polymorphism (num-
ber of Ala repeats) in GPX1 sequence was performed 
and genotypes distribution was studied in ccRCC 
patients and in the control group (healthy individuals) 
(Table 4). No deviations from Hardy — Weinberg equi-
librium was found in the both groups. Five Ala repeats 
was found in 39 (48.8 ± 5.6%), six repeats in 24 (30.0 ± 
5.1%), and seven — in 17 (21.2 ± 4.6%) of ccRCC pa-
tients. In the control group Ala repeats were distributed 
similarly: five repeats was found in 39 (47.6 ± 5.5%), 
six — in 22 (26.8 ± 4.9%), and seven — in 21 (25.6 ± 
4.8%) of healthy donors. By other words, no significant 
difference was observed between ccRCC patients and 
the control group.
As is seen from Table 4, five Ala repeats was de-
tected the most frequently in the both groups. An obvi-
ous question was to check whether the five Ala repeats 
would be found at a higher rate among ccRCC patients 
in comparison with healthy persons. No difference 
was found, however, between patients and healthy 
individuals (p = 0.944).
Table 4. Distribution of GPX1 genotype for ccRCC patients and healthy 
individuals
GPX1 (№ of Ala repeats 
on both alleles)
Renal cancer, 
n (%) (n = 40)
Control, n (%) 
(n = 41)
5/5 10 (25.0 ± 6.8) 11 (26.8 ± 6.9)
6/6 4 (10.0 ± 4.7) 2 (4.9 ± 3.4)
7/7 1 (2.5 ± 2.5) 4 (9.8 ± 4.6)
5/6 10 (25.0 ± 6.8) 11 (26.8 ± 6.9)
5/7 9 (22.5 ± 6.6) 6 (14.6 ± 5.5)
6/7 6 (15.0 ± 5.6) 7 (17.1 ± 5.9)
Heterozygote frequencies 25 (62.5 ± 7.7) 24 (58.5 ± 7.7)
Homozygote frequencies 15 (37.5 ± 7.7) 17 (41.5 ± 7.7)
GPX2. GPX2 is located on chromosome 14q24.1 and 
shows upregulated expression in colorectal cancer, 
Barrett’s esophagus, squamous cell carcinoma and 
lung adenocarcinoma of smokers. From other hand, 
it was shown that GPX2 might prevent tumorigenesis 
associated with inflammation. Hence, this gene could 
show different properties upon cell transformation, 
compared with normal cells. It was proposed that 
GPX2 may prevent initiation but support promotion 
of cancerogenesis [19]. This hypothesis is supported 
by the fact that GPX2 expression is only transiently up-
regulated in early stages of malignant transformation 
in the colon [20].
Noteworthy, no expression of GPX2 gene in the nor-
mal and tumor tissues of kidney was registered 
in the present work.
GPX3.  We have shown that  expression 
of GPX3 (located on chromosome 5q33.1) was 
decreased in ccRCC in 100% of cases. Inhibition 
of expression of GPX3 and as consequence, activity 
of GPX3 protein, might be associated with different 
stages of cancer progression, including initiation, pro-
motion, and metastasizing [21]. Moreover, GPX3 ex-
pression was downregulated in the plasma of patients 
bearing breast, gastric, and colorectal cancers. 
In cancer tissues of prostate, esophagus, and thyroid 
GPX3 expression was decreased as well [22, 16].
GPX4. Expression of GPX4 (located on chromo-
some 19p13.3) at the mRNA level was decreased 
in 81% (13/16) of samples, when tumors were com-
pared with corresponding normal tissues.
GPX4 is an ubiquitously expressed anti-oxidant 
protein that, in contrast to other GPX isoforms, resides 
in the cell membrane and can reduce and detoxify 
lipid hydroperoxides [23]. GPX4 exists in three dif-
ferent isoform, i.e. cytoplasmic, mitochondrial, and 
sperm nuclear. GPX4 plays an important role in cell 
functioning, because GPX4 knockout is embryonically 
lethal [24].
GPX6. GPX6 (located on chromosome 6p22.1) 
is restricted in expression to the developing embryo 
and olfactory epithelium in adults. This protein has not 
been yet characterized in terms of function or dise-
ase [25]. No expression of GPX6 was found in the nor-
mal and cancer kidney tissues in our study.
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Methylation profile of GPXs promoter re-
gion in ccRCC tissue samples. The CpG is-
lands in the promoter region of GPXs were de-
fined, using CpG island searcher online tool 
(http://www.uscnorris.com/cpgislands2/cpg.aspx). 
We have found CpG islands in promoter region of GPX1, 
GPX3, and GPX4, but not of GPX2 and GPX6 genes. 
25 ccRCC samples and respective normal tissues were 
analyzed, using the methyl-specific quantitative PCR 
(MSP qPCR) and primers for unmethylated and methy-
lated forms of genes. The obtained results showed 
that there was no methylation in any tumor samples. 
Hence, decreased expression of GPXs genes is not 
associated with promoter methylation.
Analysis of variations in GPXs copy number. 
Analysis of GPXs gene copy number was performed 
on 12 renal cancer samples. Changes of GPX1 gene 
copy number were observed in 92% (11/12) of RCC 
samples; 11 samples displayed ratio < 0.7 and > 0.2 and 
that was considered as heterozygous deletions. One 
sample showed ratio 1.2 and that was considered 
as unchanged status. Changes of GPX3 gene copy 
number were observed in 50% (6/12) of RCC samples. 
The ratio was > 1.4 and that was considered as am-
plification. Copy number of GPX4 was not changed 
(Table 5).
Table 5. Summary on GPXs copy number in the tumor tissues
Sample 
number TNM
Stage 
of atypia Grade
Ratio T/N
GPX1
Ratio T/N
GPX3
Ratio T/N
GPX4
1 T4NxM0 3 IV 1.2 1.1 1.1
2 T2aNxM1 3 IV 0.4 1.4 1.1
3 T2NxM1 4 IV 0.2 2.2 1.1
4 T2aNxM1 3 II 0.7 1.1 1.2
5 T4NxM0 4 IV 0.3 0.8 0.9
6 T4N0M1 3 IV 0.4 1.5 1.1
7 T3bNxM0 2 III 0.7 0.9 1.1
8 T3bNxM0 2 III 0.7 0.9 1.0
9 T1bNxM0 2 II 0.4 1.0 0.9
10 T3N1M0 3 III 0.4 1.4 0.9
11 T3N0M0 3 III 0.3 1.5 1.0
12 T3N0M0 3 III 0.6 1.5 1.0
All the data discussed above suggest that changes 
(decrease) of expression of GPXs genes are achieved 
by the different mechanisms upon cancerogenesis.
To validate our data, the bioinformatic analysis was 
performed, using cBioPortal Web resource online [26, 
27]. The cBioPortal for Cancer Genomics allow us ex-
ploring, visualizing, and analysis of multidimensional 
cancer genomics data. This portal compress the data 
on molecular profiling of different cancer tissues and 
also different data bases (for example microarrays, 
RNAseq, etc.). Large-scale cancer genomics pro jects, 
such as The Cancer Genome Atlas (TCGA) and the In-
ternational Cancer Genome Consortium (ICGC) gene-
rate an overwhelming amount of cancer geno mics data 
from the multiple different technical platforms, making 
it increasingly challenging to perform data integra-
tion, exploration, and analysis. Genetic alterations 
in 415 ccRCC were analyzed, using cBioPortal Web. 
The obtained results are shown on Figure.
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Figure. Relative expression level as a function of relative copy 
number of GPXs genes. Homdel — homozygously deleted; Het-
loss — heterozygously deleted; Diploid — two alleles present; 
Gain — low-level gene amplification event; Amp — high-level 
gene amplification event
As seen on Figure, our results are in line with 
the data obtained by other methods. So, gene 
GPX1 is he terozygously deleted, gene GPX3 showed 
the low level of gene amplification event, and for 
GPX4 no changes were observed. As was mentioned 
before, genes GPX2 and GPX6 were not expressed 
in ccRCC tumors nor in normal tissues.
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The main reasons of decreased gene expression are 
deletion, promoter methylation, and downregulation 
by proteins or miRNAs. In case of ccRCC, methyla-
tion is not a cause of decreased expression of GPXs. 
We have to mention, that decreased expression of glu-
thation peroxidases can be both, the cause and the con-
sequence of cancerogenesis; their transcription is regu-
lated by glutathione oxidative potential, which is low 
in tumors [28]. Such regulation is provided by several 
mechanisms that are common for all GPXs. First, there 
are oxygen response elements, ORE for activation or in-
hibition of transcription by “proteins-sensors” in GPX 
promoter sequence. Interestingly, hyperoxia increases 
transcription of GPX1 in endothelial cells of umbilical 
vein through a mechanism independent of ORE, sug-
gesting that transcription of GPXs in response to oxygen 
stress is regulated by more than one mechanism [29, 
30]. Second, oxidative potential in cell impacts on the 
catalytic activity of GPXs by regulating the availability 
of protein SBP2, which is required for the insertion of se-
lenium [4]. Hence, the role of GPXs in cancerogenesis 
cannot be considered only as the antioxidant proteins, 
as was mentioned above. It depends also on types and 
stage of cancer and class of GPXs [16].
Downregulation of expression of GPXs genes 
is observed at the early stages of ccRCC [31], so it can 
be one of the causes of cancer initiation. Expression 
is decreased even more upon the cancerogenesis, and 
it may be explained by two assumptions. Firstly, it may 
reduce the oxidative capacity of the cells, due to the fact 
that cancer cells are more exposed to hypoxia upon 
increase of tumor size. Secondly, the p53 protein can 
bind to the promoter of the gene as a transcription fac-
tor, thus, stimulating transcription [32, 33]. So, reduced 
expression of GPX may be explained by inactivation 
of p53 function, which is typical for majority of tumors.
CONCLUSIONS
In the present work we have found that GPX1, 
GPX3, and GPX4 genes showed decreased expres-
sion in tumors, compared with the normal tissues. 
GPX2 and GPX6 genes were not expressed in renal 
cell carcinomas cancer or normal tissues. Promoters 
of the studied genes were not methylated in renal cell 
carcinomas cancer samples. So, lowered expression 
of GPX genes is not associated with promoter methy-
lation. Other mechanism must be responsible for 
decrease of GPX expression. We have found heterozy-
gous deletions in GPX1 gene. GPX3 gene, in contrast, 
showed amplification; no changes in copy number 
of GPX4 gene was found. Despite the uncertainty what 
was a cause of decreased expression of genes (except 
GPX1), GPXs might be considered as diagnostic mar-
kers for ccRCC at the certain circumstances.
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